FDA Approves First GSDIa Therapy for Patients 8+
The FDA has issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), marking the first treatment for adults and children aged 8 years and older with glycogen storage disease type Ia (GSDIa).
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day